World neurosurgery · 2025
Percutaneous Balloon Compression Exerts Multidimensional Efficacy in Trigeminal Neuralgia via Neuroinflammation and Neurotransmitter Regulation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Du Yihui, Shi Haowei, Xi Zenghui, Wang Yinzhan, Guo Wenchang, Qian Tao
Аннотация
OBJECTIVE: This real-world study evaluated the multidimensional efficacy of percutaneous balloon compression (PBC) in trigeminal neuralgia (TN), focusing on pain relief, psychological comorbidities, quality of life, and neuroinflammation modulation.
METHODS: A retrospective analysis included 140 TN patients (68 PBC vs. 72 pharmacotherapy controls), with 57 propensity score-matched pairs. Outcomes comprised visual analog scale (VAS), Hamilton Depression/Anxiety Scales, Short Form-36 Health Survey quality of life scores, and serum biomarkers (5-hydroxytryptamine, Substance P, interleukin 1β, and tumor necrosis factor-alpha). Difference-in-differences (DID) models quantified net treatment effects; generalized estimating equations identified predictors of efficacy.
RESULTS: PBC demonstrated superior outcomes versus controls (all P < 0.05): greater VAS reduction (net DID: -0.97; 95% confidence interval: -1.41 to -0.53), Hamilton Depression Scale/Hamilton Anxiety Scale improvements, and Short Form-36 Health Survey gains (DID: +2.03). Biomarker analysis revealed significant declines in PBC-treated patients for 5-hydroxytryptamine, Substance P, interleukin 1β, and tumor necrosis factor-alpha (DID interactions P < 0.01). Total efficacy was higher with PBC (98.08% vs. 84.62%) with lower complications. Generalized estimating equation confirmed PBC intervention (β = 3.21, P = 0.002), pain reduction (βVAS_diff = -1.21, P = 0.003), and cytokine modulation as independent predictors of efficacy.
CONCLUSIONS: Beyond analgesia, PBC attenuates affective disorders and normalizes neuroinflammatory signaling in TN. Its modulation of the pain-neuroimmune axis supports integrated neuropsychiatric management strategies.
METHODS: A retrospective analysis included 140 TN patients (68 PBC vs. 72 pharmacotherapy controls), with 57 propensity score-matched pairs. Outcomes comprised visual analog scale (VAS), Hamilton Depression/Anxiety Scales, Short Form-36 Health Survey quality of life scores, and serum biomarkers (5-hydroxytryptamine, Substance P, interleukin 1β, and tumor necrosis factor-alpha). Difference-in-differences (DID) models quantified net treatment effects; generalized estimating equations identified predictors of efficacy.
RESULTS: PBC demonstrated superior outcomes versus controls (all P < 0.05): greater VAS reduction (net DID: -0.97; 95% confidence interval: -1.41 to -0.53), Hamilton Depression Scale/Hamilton Anxiety Scale improvements, and Short Form-36 Health Survey gains (DID: +2.03). Biomarker analysis revealed significant declines in PBC-treated patients for 5-hydroxytryptamine, Substance P, interleukin 1β, and tumor necrosis factor-alpha (DID interactions P < 0.01). Total efficacy was higher with PBC (98.08% vs. 84.62%) with lower complications. Generalized estimating equation confirmed PBC intervention (β = 3.21, P = 0.002), pain reduction (βVAS_diff = -1.21, P = 0.003), and cytokine modulation as independent predictors of efficacy.
CONCLUSIONS: Beyond analgesia, PBC attenuates affective disorders and normalizes neuroinflammatory signaling in TN. Its modulation of the pain-neuroimmune axis supports integrated neuropsychiatric management strategies.